Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Nov 15;23:785–798.

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Molecular Vision.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited, used for non-commercial purposes, and is not altered or transformed.

PMC Copyright notice

Efficacy of brimonidine on inhibiting progressing myopia. The alternation of refractive error (RE), axial length (AL), and intraocular pressure (IOP) during experiment in groups A, B, C, and F is shown. All values were calculated as the difference between the right eye and the left eye. A: RE changing course in 3 weeks. B: Histogram analysis of the difference in RE before and after the experiment. C: AL changing course in 3 weeks. D: Histogram analysis of the difference in AL before and after the experiment. E: IOP changing course in 3 weeks. F: Histogram analysis of the difference in the IOP before and after the experiment. *p<0.05 (n=6). (Group A: 2% pirenzepine group; Group B: 0.2% brimonidine group; Group C: 0.1% brimonidine group; Group F: medium group).